Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of once-daily oral HS-10501/HS-10501-2 in adults with overweight or obesity
CTR20251769Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10501 in obesity, Overweight, sponsored by Hengrui Therapeutics. Started May 2025; status: completed.
02
Drugs
HS-10501
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20251769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251769.